This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

MorphoSys Strengthens Clinical Development Organization With Three Management Appointments

MARTINSRIED / MUNICH, Germany, Dec. 19, 2013 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced today that it has completed the expansion of its senior clinical development team by appointing Dr. Gabriele Elbl as Head of Regulatory Affairs, Dr. Ludger Langer as Head of Clinical Operations and Project Management and most recently Dr. Steffen Heeger as Head of Clinical Research.

Gabriele Elbl joined MorphoSys after working for more than 20 years in small and large pharmaceutical companies. During this time she gained a deep understanding of all regulatory aspects of product development, both for the US and the EU. Dr. Elbl has extensive experience of development programs for biologics through interactions with both the American Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Most recently she held the position of Senior Vice President, Regulatory Affairs at Wilex AG, Munich. Prior to that she worked as a Scientific Administrator at the EMA, London, and served as Head of Pharmaceutical Department at Sanofi Winthrop in Munich. Dr. Elbl studied pharmacy and received a PhD in Pharmaceutical Biology from the Ludwig-Maximilian-University, Munich.

Ludger Langer joined MorphoSys from PRA International. He brings almost 20 years of clinical operations and project management experience to MorphoSys. Dr. Langer held several positions of increasing seniority in Clinical Operations and Project Management with a focus on planning and execution of multiregional clinical trials. Prior to joining MorphoSys, Dr. Langer was Vice President, Clinical Operations, Europe, Asia-Pacific and Africa at PRA International. Dr. Langer studied pharmacy and received a PhD from the Goethe University, Frankfurt/Main.

Steffen Heeger is an oncologist with deep experience in oncology drug development from his past ten years at Merck Serono, where he was Head of Medical Affairs and where he led the Global Clinical Development Team for Erbitux ®. Dr. Heeger studied Medicine in Freiburg, Heidelberg and Mannheim and continued his medical training at the Clinic of Hematology/Oncology of the University of Heidelberg. During this time he was also a scientist at the German Cancer Research Center (DKFZ) in Heidelberg where he worked on the development of antibody conjugates. He received a PhD in Medicine from the University of Heidelberg.

"We are very pleased to have gained three outstanding individuals for these key positions within the MorphoSys development organization," explained Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "The appointment of Gabriele Elbl and Ludger Langer earlier this year and most recently Steffen Heeger already had a significant impact on our development capabilities and underscores our strong commitment to the further expansion, development and commercialization of our proprietary drug portfolio."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs